

84424

STIC-Biotech/ChemLib

From: Mertz, Prema
Sent: Thursday, January 16, 2003 8:05 AM
To: STIC-Biotech/ChemLib
Subject: 09/911,346

Please search SEQ ID NO:2 with protein databases.

Thanks,

Prema Mertz, Ph.D.
Primary Examiner
Art Unit 1646
Crystal Mall 1, Room 10E-01
United States Patent & Trademark Office
(703) 308-4229

10D19

Point of Contact
P. Sheppard
Telephone number: (703) 308-4499

Searcher: _____
Phone: _____
Location: _____
Date Picked Up: _____
Date Completed: 1/19/03
Searcher Prep/Review: _____
Clerical: _____
Online time: _____

TYPE OF SEARCH:

NA Sequences: _____
AA Sequences: _____
Structures: _____
Bibliographic: _____
Litigation: _____
Full text: _____
Patent Family: _____
Other: _____

VENDOR/COST (where applic.)

STN: _____
DIALOG: _____
Questel/Orbit: _____
DRLink: _____
Lexis/Nexis: _____
Sequence Sys.: _____
WWW/Internet: _____
Other (specify): _____

=> s l3 (5a) (antibod?)

L4 3 L3 (5A) (ANTIBOD?)

=> d l4 1-3 bib ab

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 2001:868518 CAPLUS
DN 136:4735
TI A novel polypeptide, a human natural killer cell enhancing factor B13.64
and the polynucleotide encoding the polypeptide
IN Mao, Yumin; Xie, Yi
PA Shanghai Biowindow Gene Development Inc., Peop. Rep. China
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA Chinese
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO.
DATE
PI WO 2001090177 A1 20011129 WO 2001-CN855
20010521
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,
BZ, CA, CH, CO,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE,
GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ,
PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW,
AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD,
TG
CN 1324837 A 20011205 CN 2000-115801
20000524
PRAI CN 2000-115801 A 20000524
AB The present invention discloses a novel polypeptide, a human
natural
killer cell enhancing factor B13.64, the polynucleotide encoding
the
polypeptide and the method for producing the polypeptide by
DNA
recombinant technol. The invention also discloses the uses of the
polypeptide in methods for treating various diseases, such as
malignant
tumor, hemopathy, development disturbance disease, HIV
infection, immunol.
disease and various inflammation etc. The invention also
discloses the
agonists against the polypeptide and the therapeutic action thereof.

The
invention also discloses the uses of the polynucleotide encoding
the novel
human natural killer cell enhancing factor B13.64.
RE.CNT 5 THERE ARE 5 CITED REFERENCES
AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1997:151433 CAPLUS
DN 126:153669
TI Cloning and cDNA sequence of human natural killer cell
enhancing factor C
and its diagnostic and therapeutic uses
IN Ni, Jian; Yu, Guo-Liang; Gentz, Reiner; Rosen, Craig A.
PA Human Genome Sciences, Inc., USA; Ni, Jian; Yu, Guo-Liang;
Gentz, Reiner;
Rosen, Craig A.
SO PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO.
DATE
PI WO 9639424 A1 19961212 WO 1995-US7200
19950606
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE,
DK, ES, FI, GB,
GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD,
MG, MN, MW,
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT,
UA, US, UZ, VN
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR,
GB, GR, IE, IT,
LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
ML, MR, NE,
SN, TD, TG
AU 9528186 A1 19961224 AU 1995-28186
19950606
PRAI WO 1995-US7200 19950606
AB The cDNA sequence and the corresponding deduced amino acid
sequence of
protein putatively identified as a natural killer cell enhancing
factor
(NKEF C) are provided. The cDNA was discovered in a cDNA
library derived
from cycloheximide-treated CEM cells. It is highly expressed in
heart,
liver, skeletal muscle, pancreas, testis, and ovary; moderately
expressed
in placenta, lung, prostate, small intestine, and colon; and lowly
expressed in brain, spleen, thymus, and peripheral blood
leukocyte. It is
structurally related to a family of highly conserved oxidative stress
genes. It contains an open reading frame encoding a protein of
271 amino
acid residues, of which approx. the first 30 amino acid residues
are the
putative leader sequence such that the mature protein comprises

241 amino acids. The protein exhibits the highest degree of homol. to NKEF B expressed from NK-sensitive erythroleukemia cell line K562 with 68.182% identity and 83.333% similarity over the entire amino acid stretch. Recombinant techniques for expression of NKEF C are described, including (1) bacterial expression using the Escherichia coli expression vector pQE-9, (2) expression in COS cells using the pcDNA1/Amp vector, (3) cloning and expression using the baculovirus expression system with the pA2 vector (a modification of the pVL941 vector) in Sf9 cells, and (4) expression via gene therapy with the pMV-7 vector based on the Moloney murine sarcoma virus backbone. Diagnostic methods for detecting a mutation in the NKEF C nucleic acid sequence and detecting altered levels of polypeptide for detecting diseases are also disclosed. NKEF C exhibits growth inhibitory effects against human leukemia cells and antiviral activity against vesicular stomatitis virus. It can be used for preventing and/or treating viral infections, inflammation, neoplasia, and damage from superoxide radicals.

L4 ANSWER 3 OF 3 USPATFULL
 AN 97:20653 USPATFULL
 TI DNA's encoding natural killer cell enhancing factor
 IN Shau, Hungyi, Cerritos, CA, United States
 Golub, Sidney H., Los Angeles, CA, United States
 PA The Regents Of The University Of California, Oakland, CA, United States
 (U.S. corporation)
 PI US 5610286 19970311
 AI US 1994-299162 19940831 (8)
 RLI Continuation-in-part of Ser. No. US 1994-232189, filed on 3 May 1994,
 now abandoned which is a continuation-in-part of Ser. No. US 1991-787148, filed on 4 Nov 1991, now patented, Pat. No. US 5250295
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Ulm, John; Assistant Examiner: Mertz, Prema
 LREP Poms, Smith, Lande & Rose
 CLMN Number of Claims: 2
 ECL Exemplary Claim: 1
 DRWN 3 Drawing Figure(s); 3 Drawing Page(s)
 LN.CNT 1323
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Recombinant DNA molecules comprising a DNA sequence encoding either NKEF (Natural Killer Enhancing Factor) A or B or their amino acid sequence variants. Essentially pure natural killer enhancing factor comprising the amino acid sequence of NKEF A or B or their amino acid sequence variants. Compositions of matter for use in enhancing the activity of natural killer cells; the composition comprising an anchor moiety to which is linked either NKEF A or B or their amino acid sequence variants. Methods for enhancing the in vivo activity of natural killer

cells; the methods comprising introducing in vivo a sufficient amount of either NKEF A or B or their amino acid sequence variants linked to an anchor moiety. In a method for inducing leukocyte activation and proliferation wherein the leukocytes are treated with a cytokine the improvement comprising treating the leukocytes with the cytokine in the presence of NKEF A or B or their amino acid sequence variants.

=> d his

(FILE 'HOME' ENTERED AT 12:10:29 ON 16 JAN 2003)

FILE 'MEDLINE, CAPLUS, USPATFULL' ENTERED AT 12:10:50 ON 16 JAN 2003
 L1 0 S KILLER CELL ENHANCING FACTOR#
 L2 39 S KILLER CELL ENHANCING FACTOR
 L3 40 S KILLER CELL ENHANCING FACTOR#
 L4 3 S L3 (5A) (ANTIBOD?)